Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon.

ABSTRACT:

Objective

To evaluate the effectiveness and safety of tofacitinib in patients with ulcerative colitis (UC) in clinical practice in Lebanon.

Design

This was a retrospective cross-sectional study. The data were collected from hospital records. Patients with moderate to severe UC treated with tofacitinib between 2018 and 2021 were included. Patients' demographics, disease-specific characteristics, clinical assessment at three time points (8, 26, and 52 weeks), endoscopic evaluation at 24 weeks, and adverse events were collected.

Results

A total of 60 UC patients with a mean duration of disease of 7.9 ± 4.7 years were enrolled. 61.7% of patients had extensive disease, and 58.3% had received ≥ 1 biologic prior to tofacitinib. Clinical remission was reported in 25, 34, and

SUBMITTER: Sharara AI 

PROVIDER: S-EPMC11451213 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature